Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: Described herein are materials and methods for the treatment of neurodegenerative diseases by administering a combination of fenofibrate and kaempferol.

Abstract: The present invention relates to methods of determining if a subject has a decreased risk of suffering from future memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has a decreased risk of suffering from future memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's meta-bolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's proteomic profile and comparing the value of the subject's proteomic profile with the value of a normal proteomic profile. A change in the value of the subject's proteomic profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing the gene expression profile from peripheral blood leukocytes taken from the subject and comparing the value of the subject's gene expression profile with the value of a normal gene expression profile. A change in the value of the subject's gene expression profile, above or below normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and comparing the value of the subject's lipidomic profile with the value of a normal lipidomic profile. A decrease in the value of the subject's lipidomic profile over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has a decreased risk of suffering from future memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has a decreased risk of suffering from future memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's proteomic profile and comparing the value of the subject's proteomic profile with the value of a normal proteomic profile. A change in the value of the subject's proteomic profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing the gene expression profile from peripheral blood leukocytes taken from the subject and comparing the value of the subject's gene expression profile with the value of a normal gene expression profile. A change in the value of the subject's gene expression profile, above or below normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one sample from the subject to determine a value of the subject's exosomal profile or combined biomarker profile (lipids plus exosomal cargo) and comparing the value of the subject's exosomal or combined biomarker profile with the value of a normal exosomal or biomarker profile, respectively. A change in the value of the subject's exosomal or combined biomarker profile, including a change in the subject's exosomal or combined biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and also analyzing the gene expression profile from leukocytes and comparing the value of the subject's biomarker profile (lipidomic profile plus gene expression profile) with the value of a normal biomarker profile. A change in the value of the subject's biomarker profile, including a change in the subject's biomarker profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.

Abstract: The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's lipidomic profile, and comparing the value of the subject's lipidomic profile with the value of a normal lipidomic profile. A decrease in the value of the subject's lipidomic profile over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.